{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:24:25Z","timestamp":1792265065224,"version":"4.4.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ejca.2023.113287","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T11:43:09Z","timestamp":1691408589000},"page":"113287","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Stereotactic radiosurgery and anti-PD-1\u00a0+\u00a0CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF\/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastases"],"prefix":"10.1016","volume":"192","author":[{"given":"Ammoren E.","family":"Dohm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyn Y.","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hruday","family":"Kalagotla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley X.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menal","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2307-0330","authenticated-orcid":false,"given":"Youngchul","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine A.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil I.","family":"Khushalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Forsyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold B.","family":"Etame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James K.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nam D.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Vogelbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan J.","family":"Wuthrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiang-Hsuan Michael","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran A.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.113287_bib1","first-page":"741","article-title":"New era in the management of melanoma brain metastases","volume":"38","author":"Tawbi","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book\/ASCO Am Soc Clin Oncol Meeting"},{"key":"10.1016\/j.ejca.2023.113287_bib2","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/pcmr.12771","article-title":"Melanoma central nervous system metastases: an update to approaches, challenges, and opportunities","volume":"32","author":"Eroglu","year":"2019","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.ejca.2023.113287_bib3","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.113287_bib4","first-page":"4737","article-title":"Primary analysis and 4-year follow-up of the phase III NIBIT-M2 trial in melanoma patients with brain metastases","volume":"27","author":"Di Giacomo","year":"2021","journal-title":"Clin\u00a0Cancer Res"},{"key":"10.1016\/j.ejca.2023.113287_bib5","first-page":"113","article-title":"Immunotherapy for brain metastases and primary brain tumors","volume":"179","author":"Di Giacomo","year":"2023","journal-title":"Eur\u00a0J\u00a0Cancer"},{"key":"10.1016\/j.ejca.2023.113287_bib6","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/S1470-2045(21)00545-3","article-title":"Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study","volume":"22","author":"Tawbi","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.113287_bib7","first-page":"434","article-title":"Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy","volume":"27","author":"Ahmed","year":"2016","journal-title":"Ann\u00a0Oncol"},{"key":"10.1016\/j.ejca.2023.113287_bib8","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3892\/or.2012.2139","article-title":"Stereotactic radiosurgery for the treatment of melanoma and renal cell carcinoma brain metastases","volume":"29","author":"Lwu","year":"2013","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ejca.2023.113287_bib9","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/CMR.0000000000000250","article-title":"Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases","volume":"26","author":"Patel","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2023.113287_bib10","article-title":"Stereotactic radiosurgery and combined immune checkpoint therapy with ipilimumab and nivolumab in patients with melanoma brain metastases: a retrospective monocentric toxicity analysis","volume":"39","author":"Bodensohn","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ejca.2023.113287_bib11","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/jamaoncol.2017.3993","article-title":"Immunotherapy and symptomatic radiation necrosis in patients with brain metastases treated with stereotactic radiation","volume":"4","author":"Martin","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2023.113287_bib12","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1227\/neu.0000000000002127","article-title":"Concurrent administration of immune checkpoint inhibitors and stereotactic radiosurgery is well-tolerated in patients with melanoma brain metastases: an international multicenter study of 203 patients","volume":"91","author":"Lehrer","year":"2022","journal-title":"Neurosurgery"},{"key":"10.1016\/j.ejca.2023.113287_bib13","first-page":"2288","article-title":"Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF\/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy","volume":"27","author":"Ahmed","year":"2016","journal-title":"Ann\u00a0Oncol"},{"key":"10.1016\/j.ejca.2023.113287_bib14","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: proposal from the RANO group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.113287_bib15","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.113287_bib16","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.113287_bib17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11060-014-1685-x","article-title":"LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases","volume":"122","author":"Ahmed","year":"2015","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.ejca.2023.113287_bib18","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1200\/JCO.21.02961","article-title":"Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): a randomized, three-arm, open-label phase II trial","volume":"41","author":"Ascierto","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113287_bib19","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1200\/JCO.21.02314","article-title":"Treatment for brain metastases: ASCO-SNO-ASTRO guideline","volume":"40","author":"Vogelbaum","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113287_bib20","first-page":"1261","article-title":"Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases","volume":"123","author":"Frakes","year":"2015","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.ejca.2023.113287_bib21","first-page":"181","article-title":"Local control of melanoma brain metastases treated with stereotactic radiosurgery","volume":"4","author":"Bagshaw","year":"2016","journal-title":"J Radiosurg SBRT"},{"key":"10.1016\/j.ejca.2023.113287_bib22","article-title":"Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: a nonrandomized, open-label phase 1b study","volume":"6","author":"Ahmed","year":"2021","journal-title":"Adv Radiat Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923003891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923003891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:42:08Z","timestamp":1760733728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923003891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":22,"alternative-id":["S0959804923003891"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113287","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic radiosurgery and anti-PD-1\u00a0+\u00a0CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF\/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113287","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113287"}}